Osvyrti is suppled as a 60mg/mL single-dose prefilled syringe for SC administration and Jubereq is supplied as 120mg/1.7mL single-dose vial for SC administration.

According to the US Department of Health and Human Services, research plans to investigate all the possible causes of autism are in the works.

Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo ...

Proportion of physicians with MHSU care stable prepandemic, then increased, with larger increases seen during first two years of pandemic.

The prevalence of childhood hypertension nearly doubled between 2000 and 2020, from 3.40 to 6.53% in boys and from 3.02 to 5.82% in girls. HealthDay News — The prevalence of childhood hypertension is ...

Increased rate of major bleeding and lower mortality rates observed, resulting in greater net clinical benefit.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Darzalex Faspro ® is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase that increases permeability of the subcutaneous ...

The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously, ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.